PortalPublikationenRituximab in adult patients with immunosuppressive-dependent...

Rituximab in adult patients with immunosuppressive-dependent minimal change disease.

Standard

Rituximab in adult patients with immunosuppressive-dependent minimal change disease. / Hoxha, Elion; Stahl, Rolf A.K.; Harendza, Sigrid.

in: CLIN NEPHROL, Jahrgang 76, Nr. 2, 2, 2011, S. 151-158.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hoxha, E, Stahl, RAK & Harendza, S 2011, 'Rituximab in adult patients with immunosuppressive-dependent minimal change disease.', CLIN NEPHROL, Jg. 76, Nr. 2, 2, S. 151-158. <http://www.ncbi.nlm.nih.gov/pubmed/21762648?dopt=Citation>

APA

Hoxha, E., Stahl, R. A. K., & Harendza, S. (2011). Rituximab in adult patients with immunosuppressive-dependent minimal change disease. CLIN NEPHROL, 76(2), 151-158. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21762648?dopt=Citation

Vancouver

Hoxha E, Stahl RAK, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. CLIN NEPHROL. 2011;76(2):151-158. 2.

Bibtex

@article{612c70dc287848239908bf9d30d9d7d6,
title = "Rituximab in adult patients with immunosuppressive-dependent minimal change disease.",
abstract = "Minimal change disease (MCD) is one of the leading causes of nephrotic syndrome. Steroid therapy is effective in achieving remission, but relapses, steroid dependence, and steroid resistance are therapeutic challenges. The use of second-line agents such as cyclophosphamide is associated with toxicity and adverse effects. Therefore, we studied the effect of rituximab (RTX) on proteinuria in adult patients with immunosuppressive (IS)-dependent MCD.",
keywords = "Adult, Humans, Male, Female, Prospective Studies, Treatment Outcome, Recurrence, Remission Induction, Antineoplastic Agents/*therapeutic use, Immunosuppressive Agents/*therapeutic use, Antibodies, Monoclonal, Murine-Derived/*therapeutic use, Nephrosis, Lipoid/*drug therapy/immunology, Nephrotic Syndrome/*drug therapy, Proteinuria/*drug therapy, Adult, Humans, Male, Female, Prospective Studies, Treatment Outcome, Recurrence, Remission Induction, Antineoplastic Agents/*therapeutic use, Immunosuppressive Agents/*therapeutic use, Antibodies, Monoclonal, Murine-Derived/*therapeutic use, Nephrosis, Lipoid/*drug therapy/immunology, Nephrotic Syndrome/*drug therapy, Proteinuria/*drug therapy",
author = "Elion Hoxha and Stahl, {Rolf A.K.} and Sigrid Harendza",
year = "2011",
language = "English",
volume = "76",
pages = "151--158",
journal = "CLIN NEPHROL",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

RIS

TY - JOUR

T1 - Rituximab in adult patients with immunosuppressive-dependent minimal change disease.

AU - Hoxha, Elion

AU - Stahl, Rolf A.K.

AU - Harendza, Sigrid

PY - 2011

Y1 - 2011

N2 - Minimal change disease (MCD) is one of the leading causes of nephrotic syndrome. Steroid therapy is effective in achieving remission, but relapses, steroid dependence, and steroid resistance are therapeutic challenges. The use of second-line agents such as cyclophosphamide is associated with toxicity and adverse effects. Therefore, we studied the effect of rituximab (RTX) on proteinuria in adult patients with immunosuppressive (IS)-dependent MCD.

AB - Minimal change disease (MCD) is one of the leading causes of nephrotic syndrome. Steroid therapy is effective in achieving remission, but relapses, steroid dependence, and steroid resistance are therapeutic challenges. The use of second-line agents such as cyclophosphamide is associated with toxicity and adverse effects. Therefore, we studied the effect of rituximab (RTX) on proteinuria in adult patients with immunosuppressive (IS)-dependent MCD.

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Prospective Studies

KW - Treatment Outcome

KW - Recurrence

KW - Remission Induction

KW - Antineoplastic Agents/therapeutic use

KW - Immunosuppressive Agents/therapeutic use

KW - Antibodies, Monoclonal, Murine-Derived/therapeutic use

KW - Nephrosis, Lipoid/drug therapy/immunology

KW - Nephrotic Syndrome/drug therapy

KW - Proteinuria/drug therapy

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Prospective Studies

KW - Treatment Outcome

KW - Recurrence

KW - Remission Induction

KW - Antineoplastic Agents/therapeutic use

KW - Immunosuppressive Agents/therapeutic use

KW - Antibodies, Monoclonal, Murine-Derived/therapeutic use

KW - Nephrosis, Lipoid/drug therapy/immunology

KW - Nephrotic Syndrome/drug therapy

KW - Proteinuria/drug therapy

M3 - SCORING: Journal article

VL - 76

SP - 151

EP - 158

JO - CLIN NEPHROL

JF - CLIN NEPHROL

SN - 0301-0430

IS - 2

M1 - 2

ER -